The clinical implication of this finding is that the CD4:CD8 ratio should be taken into account during adoptive transfusion of CAR- or TCR-T cells as anti-cancer treatment to improve the effect of adoptive reinfusion and reduce inflammatory cytokine storms. The gene discussed is CD4; the disease is cancer.